Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
What degree of treatment related hypocalcemia would you tolerate with denosumab before switching agents?
Related Questions
How soon after a fracture would it be safe to start anti-resorptive therapy?
How would you manage a patient with discordant TBS adjusted T-score and traditional T-score?
What patient factors are most important when considering who needs a broader workup for osteoporosis prior to starting therapy? If you workup all patients, what labs do you find most helpful to start with?
How do you counsel patients on the risks and benefits of strontium supplements for osteoporosis management?
What is your experience with using anabolic therapy for treatment of osteoporosis in patients with EtOH cirrhosis and is one agent preferred over another (PTH analogue vs Evenity)?
When transitioning from romosozumab to alendronate or teriparatide to alendronate, is there a minimum amount of time that alendronate needs to be continued to prevent loss of BMD gains?
When stopping denosumab and transitioning to PO bisphosphonate, do you wait for 6 months after the last denosumab injection to start PO bisphosphonate?
Is it safe to continue teriparatide beyond 3 years in a patient with severe osteoporosis and atypical fracture of the femur?
Would you use a parathyroid hormone analog for treatment of osteoporosis in a patient with mildly elevated AlkPhos of unclear etiology?
In a patient with severe osteoporosis (T-score -3.9) and multiple vertebral fractures in the setting of multiple myeloma with bone involvement, would you consider adding an anabolic agent such as romosozumab or teriparatide despite concerns about osteosarcoma risk?
